Off-label uses of rituximab in dermatology

被引：27

作者：

Carr, David R. ^{[1
]}

Heffernan, Michael P. ^{[1
]}

机构：

[1] Wright State Univ, Sch Med, Div Dermatol, Dayton, OH 45408 USA

来源：

DERMATOLOGIC THERAPY | 2007年 / 20卷 / 04期

关键词：

biologics; rituximab;

D O I：

10.1111/j.1529-8019.2007.00141.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Since its approval in 1997 by the FDA, rituximab has been approved for use in certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Over the past 10 years, many case reports have indicated rituximab's efficacy in a number of inflammatory conditions in dermatology. This article includes a review of the mechanism of action, dosing, and side effect profile, as well as a review of the current literature on off-label uses of the CD20(+) B-cell antagonist rituximab.

引用

页码：277 / 287

页数：11

共 115 条

[91] CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse [J].

Saito, E ;

Fujimoto, M ;

Hasegawa, M ;

Komura, K ;

Hamaguchi, Y ;

Koburagi, Y ;

Nagaoka, T ;

Takehara, K ;

Tedder, TF ;

Sato, S .

JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (11) :1453-1462

[92] Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder [J].

Salopek, TG ;

Logsetty, S ;

Tredget, EE .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (05) :785-788

[93] Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20 [J].

Sansonno, D ;

De Re, V ;

Lauletta, G ;

Tucci, FA ;

Boiocchi, M ;

Dammacco, F .

BLOOD, 2003, 101 (10) :3818-3826

[94] Skin involvement in dermatomyositis [J].

Santmyire-Rosenberger, B ;

Dugan, EM .

CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (06) :714-722

[95]

Schadlow Monica B, 2003, J Drugs Dermatol, V2, P564

[96] Rituximab in autoimmune bullous diseases:: mixed responses and adverse effects [J].

Schmidt, E. ;

Seitz, C. S. ;

Benoit, S. ;

Broecker, E. B. ;

Goebeler, M. .

BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (02) :352-356

[97] Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab [J].

Schmidt, E ;

Benoit, S ;

Bröcker, EB ;

Zillikens, D ;

Goebeler, M .

ARCHIVES OF DERMATOLOGY, 2006, 142 (02) :147-150

[98] Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab [J].

Schmidt, E ;

Herzog, S ;

Bröcker, EB ;

Zillikens, D ;

Goebeler, M .

BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (02) :449-451

[99] Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity [J].

Shustov, A ;

Luzina, I ;

Nguyen, P ;

Papadimitriou, JC ;

Handwerger, B ;

Elkon, KB ;

Via, CS .

JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (06) :R39-R47

[100] Rituximab therapy and autoimmune disorders - Prospects for anti-B cell therapy [J].

Silverman, GJ ;

Weisman, S .

ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1484-1492

← 3 4 5 6 7 8 9 10 11 12 →